Advertisement

Reactions Weekly

, Volume 1774, Issue 1, pp 298–298 | Cite as

Trametinib

Acquired drug resistance with off-label treatment: case report
Case report
  • 22 Downloads

Reference

  1. Homicsko KG, et al. Targeting MAP2K1 mutation with trametinib in a triple wild-type melanoma patient. Journal of Clinical Oncology 37 (Suppl. 15): abstr. e21027, May 2019. Available from: URL: http://doi.org/10.1200/JCO.2019.37.15_suppl.e21027 [abstract] - Switzerland

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations